Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes

被引:49
作者
Hargadon, Kristian M.
Brinkman, C. Colin
Sheasley-O'Neill, Stacey L.
Nichols, Lisa A.
Bullock, Timothy N. J.
Engelhard, Victor H.
机构
[1] Univ Virginia, Sch Med, Carter Immunol Ctr, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA
[3] Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA
[4] Univ Virginia, Hlth Syst, Human Immune Therapy Ctr, Charlottesville, VA 22908 USA
关键词
D O I
10.4049/jimmunol.177.9.6081
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD8 T cells lacking effector activity have been recovered from lymphoid organs of mice and patients with progressing tumors. We explored the basis for lack of effector activity in tumor-bearing mice by evaluating Ag presentation and CD8 T cell function in lymphoid organs over the course of tumor outgrowth. Early after tumor injection, cross-presentation by bone marrow-derived APC was necessary for T cell activation, inducing proliferation and differentiation into IFN-gamma-producing, cytolytic effectors. At later stages of outgrowth, tumor metastasized to draining lymph nodes. Both cross- and direct presentation occurred, but T cell differentiation induced by either modality was incomplete (proliferation without cytokine production). T cells within tumor-infiltrated nodes differentiated appropriately if Ag was presented by activated, exogenous dendritic cells. Thus, activated T cells lacking effector function develop through incomplete differentiation in the lymph nodes of late-stage tumor-bearing mice, rather than through suppression of previously differentiated cells.
引用
收藏
页码:6081 / 6090
页数:10
相关论文
共 54 条
[1]   Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells [J].
Albert, ML ;
Jegathesan, M ;
Darnell, RB .
NATURE IMMUNOLOGY, 2001, 2 (11) :1010-1017
[2]   Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].
Almand, B ;
Clark, JI ;
Nikitina, E ;
van Beynen, J ;
English, NR ;
Knight, SC ;
Carbone, DP ;
Gabrilovich, DI .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689
[3]  
Aruga A, 1997, J IMMUNOL, V159, P664
[4]  
Bai XF, 2001, CANCER RES, V61, P6860
[5]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[6]   Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes [J].
Blohm, U ;
Roth, E ;
Brommer, K ;
Dumrese, T ;
Rosenthal, FM ;
Pircher, H .
JOURNAL OF IMMUNOLOGY, 2002, 169 (10) :5522-5530
[7]   FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity [J].
Brinkmann, V ;
Lynch, KR .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (05) :569-575
[8]   Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells [J].
Bullock, TNJ ;
Mullins, DW ;
Engelhard, VH .
JOURNAL OF IMMUNOLOGY, 2003, 170 (04) :1822-1829
[9]   The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice [J].
Bullock, TNJ ;
Colella, TA ;
Engelhard, VH .
JOURNAL OF IMMUNOLOGY, 2000, 164 (05) :2354-2361
[10]   COSTIMULATION OF T-CELLS FOR TUMOR-IMMUNITY [J].
CHEN, LP ;
LINSLEY, PS ;
HELLSTROM, KE .
IMMUNOLOGY TODAY, 1993, 14 (10) :483-486